Loading...
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study
BACKGROUND. Ixabepilone is an effective chemotherapy in metastatic breast cancer that has been pretreated with anthracyclines and is resistant or refractory to taxanes. Adjuvant dose-dense (DD) chemotherapy is more effective than regimens administered every 3 weeks, especially in hormonal receptor (...
Saved in:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Language: | Inglês |
Published: |
AlphaMed Press
2013
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3755929/ https://ncbi.nlm.nih.gov/pubmed/23939283 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0222 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|